Takeaway
- There was no significant association between circulating levels of serum 25-hydroxyvitamin D (25[OH]D) and the risk of ductal carcinoma in situ (DCIS) of the breast, either overall or by menopausal status.
Why This Matters
- Higher circulating levels of serum 25(OH)D have been associated with a lower risk of developing invasive breast cancer.
- However, the association between the serum 25(OH)D level and the risk of DCIS of the breast has not been explored in detail.
Study Design
- The study included 231,203 women (age, 40-69 years), identified from the UK Biobank (2006-2010).
- The association between circulating levels of serum 25(OH)D and the risk of DCIS was evaluated across different quartiles.
- Funding: None disclosed.
Key Results
- Over a median follow-up of 11.3 years, 1340 DCIS cases were reported.
- No significant association was seen between serum 25(OH)D levels and DCIS risk, overall or by menopausal status (adjusted HR [aHR]; 95% CI):
- overall: quartile 4 vs 1 (0.95; 0.81 to 1.11);
- pre-menopausal status: quartile 4 vs 1 (0.97; 0.72 to 1.31); and
- post-menopausal status: quartile 4 vs 1 (0.94; 0.78 to 1.13).
- There was no linear association between increasing serum 25(OH)D levels and DCIS risk.
- The association between serum 25(OH)D levels and DCIS risk was not modified by body mass index category, family history of breast cancer, and current use of menopausal hormone therapy.
Limitations
- There was no data on mammogram screening during follow-up.
References
References
